1. Nieschlag E, Behre HM (eds) 1998 Testosterone: Action-Deficiency-Substitution, 2nd ed. Springer, Berlin

2. Hall PF 1988 Testicular steroid synthesis: organization and regulation. In: Knobil E, Neill J (eds) The Physiology of Reproduction. Raven Press, New York, pp 975-998

3. Neaves WB, Johnson L, Porter JC, Parker CR, Petty CS 1984 Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J Clin Endocrinol Metab 55:756-763

4. Seedorf U, Ellinghaus P, Roch Nofer J 2000 Sterol carrier protein-2. Biochim Biophys Acta 1486:45-54

5. Stocco DM 2001 Tracking the role of a star in the sky of the new millennium. Mol Endocrinol 15:1245-54

6. Papadopoulos V, Amri H, Li H, Yao Z, Brown RC, Vidic B, Culty M 2001 Structure, function and regulation of the mitochondrial peripheral-type benzodiazepine receptor. Therapie 56:549-56

7. Gray A, Berlin JA, McKinlay JB, Longcope C 1991 An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 44:671-684

8. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR 2001 Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724-31.

9. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB 2002 Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87:589-98.

10. Nieschlag E, Lammers U, Freischem CW, Langer K, Wickings EJ 1982 Reproductive function in young fathers and grandfathers. J Clin Endocrinol Metab 55:676-681

11. Handelsman DJ, Staraj S 1985 Testicular size: the effects of aging, malnutrition and illness. J Androl 6:144-151

12. Gray A, Feldman HA, McKinlay JB, Longcope C 1991 Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachussetts Male Aging Study. J Clin Endocrinol Metab 73:1016-1025

13. Deslypere JP, Kaufman JM, Vermeulen T, Vogelaers D, Vandalem JL, Vermeulen A 1987 Influence of age on pulsatile luteinizing hormone release and responsiveness of the gonadotrophs to sex hormone feedback in men. J Clin Endocrinol Metab 64:68-73

14. Vermeulen A, Desylpere JP, Kaufman JM 1989 Influence of antiopioids on luteinizing hormone pulsatility in aging men. J Clin Endocrinol Metab 68:68-72

15. Veldhuis JD, Urban RJ, Lizarralde G, Johnson ML, Iranmanesh A 1992 Attenuation of luteinizing hormone secretory burst amplitude as a proximate basis for the hypoandrogenism of healthy aging men. J Clin Endocrinol Metab 75:707-713

16. Veldhuis JD 2000 Recent neuroendocrine facets of male reproductive aging. Exp Gerontol 35:1281-308

17. Veldhuis JD, Zwart A, Mulligan T, Iranmanesh A 2001 Muting of androgen negative feedback unveils impoverished gonadotropin-releasing hormone/luteinizing hormone secretory reactivity in healthy older men. J Clin Endocrinol Metab 86:529-35

18. Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD 1995 Amplified nocturnal luteinizing hormone (LH) secretory burst frequency with selective attenuation of pulsatile (but not basal) testosterone secretion in healthy aged men: possible Leydig cell desensitization to endogenous LH signaling--a clinical research center study. J Clin Endocrinol Metab 80:3025-31

19. Mulligan T, Iranmanesh A, Veldhuis JD 2001 Pulsatile iv infusion of recombinant human LH in leuprolide-suppressed men unmasks impoverished Leydig-cell secretory responsiveness to midphysiological LH drive in the aging male. J Clin Endocrinol Metab 86:5547-53

20. Mulligan T, Iranmanesh A, Kerzner R, Demers LW, Veldhuis JD 1999 Two-week pulsatile gonadotropin releasing hormone infusion unmasks dual (hypothalamic and Leydig cell) defects in the healthy aging male gonadotropic axis. Eur J Endocrinol 141:257-66

21. Pincus SM, Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD 1996 Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males. Proc Natl Acad Sci U S A 93:14100-5

22. Oesterling JE, Epstein JI, Walsh PC 1986 The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. J Urol 136:1030-4

23. Prostate Cancer Trialists' Collaborative Group 2000 Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355:1491-8

24. Arlt W, Justl HG, Callies F, Reincke M, Hubler D, Oettel M, Ernst M, Schulte HM, Allolio B 1998 Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab 83:1928-34

25. Young J, Couzinet B, Nahoul K, Brailly S, Chanson P, Baulieu EE, Schaison G 1997 Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans. Journal of Clinical Endocrinology & Metabolism 82:2578-85

26. Gurpide E 1975 Tracer Methods in Hormone Research. Springer, New York

27. Setchell BP 1978 The Mammalian Testis. Paul Elek, London

28. Southren AL, Gordon GG, Tochimoto S 1968 Further studies of factors affecting metabolic clearance rate of testosterone in man. J Clin Endocrinol Metab 28:1105-1112

29. Santner S, Albertson B, Zhang GY, Zhang GH, Santulli M, Wang C, Demers LM, Shackleton C, Santen RJ 1998 Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. J Clin Endocrinol Metab 83:2104-9

30. Wang C, Catlin DH, Starcevic B, Leung A, DiStefano E, Lucas G, Hull L, Swerdloff RS 2004 Testosterone metabolic clearance and production rates determined by stable isotope dilution/tandem mass spectrometry in normal men: influence of ethnicity and age. J Clin Endocrinol Metab 89:2936-41

31. Ishimaru T, Edmiston WA, Pages L, Horton R 1978 Splanchnic extraction and conversion of testosterone and dihydrotestosterone in man. Journal of Clinical Endocrinology & Metabolism 46:528-33

32. Longcope C, Sato K, McKay C, Horton R 1984 Aromatization by splanchnic tissue in men. Journal of Clinical Endocrinology & Metabolism 58:1089-93

33. Bremner WJ, Vitiello MV, Prinz PN 1983 Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 56:1278-1281

34. Veldhuis JD, King JC, Urban RJ, Rogol AD, Evans WS, Kolp LA, Johnson ML 1987 Operating charactristics of the male hypothalamo-pituitary-gonadal axis: pulsatile release of testosterone and follicle-stimulating hormone and their temporal coupling with luteinizing hormone. J Clin Endocrinol Metab 65:929-941

35. Petra P, Stanczyk FZ, Namkung PC, Fritz MA, Novy ML 1985 Direct effect of sex-steroid binding protein (SBP) of plasma on the metabolic clearance rate of testosterone in the rhesus macaque. J Steroid Biochem Mol Biol 22:739-746

36. Petra PH 1991 The plasma sex steroid binding protein (SBP or SHBG). A critical review of recent developments on the structure, molecular biology and function. J Steroid Biochem Mol Biol 40:735-753

37. von Schoultz B, Carlstrom K 1989 On the regulation of sex-hormone-binding globulin. A challenge of an old dogma and outlines of an alternative mechanism. J Steroid Biochem Mol Biol 32:327-334

38. Pardridge WM 1987 Plasma protein-mediated transport of steroid and thyroid hormones. Am J Physiol 252:E157-64

39. Mendel CM 1989 The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev 10:232-274

40. Ekins R 1990 Measurement of free hormones in blood. Endocr Rev 11:5-46

41. Rosner W 1997 Errors in the measurement of plasma free testosterone. Journal of Clinical Endocrinology & Metabolism 82:2014-5

42. Winters SJ, Kelley DE, Goodpaster B 1998 The analog free testosterone assay: are the results in men clinically useful? Clin Chem 44:2178-82

43. Rosner W 2001 An extraordinarily inaccurate assay for free testosterone is still with us. J Clin Endocrinol Metab 86:2903.

44. Kapoor P, Luttrell BM, Williams D 1993 The free androgen index is not valid for adult males. J Steroid Biochem Mol Biol 45:325-6

45. Kumar N, Crozat A, Li F, Catterall JF, Bardin CW, Sundaram K 1999 7alpha-methyl-19-nortestosterone, a synthetic androgen with high potency: structure-activity comparisons with other androgens. J Steroid Biochem Mol Biol 71:213-22

46. Deslypere JP, Young M, Wilson JD, McPhaul MJ 1992 Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 88:15-22

47. Zhou ZX, Lane MV, Kemppainen JA, French FS, Wilson EM 1995 Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9:208-18

48. Russell DW, Wilson JD 1994 Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 63:25-61

49. Thigpen AE, Davis DL, Milatovich A, Mendonca B, Imperato-McGinley J, Griffin JE, Francke U, Wilson JD, Russell DW 1992 Molecular genetics of steroid 5a-reductase 2 deficiency. Journal of Clinical Investigations 90:799-809

50. Imperato-McGinley J, Peterson RE, Gautier T, Sturla E 1979 Androgens and the evolution of male gender identity among male pseudohemaphrodites with 5-a reductase deficiency. N Engl J Med 300:1233-1237

51. Imperato-McGinley J, Gautier T, Zirinsky K, Hom T, Palomo O, Stein E, Vaughan ED, Markisz JA, deArellano ER, Kazam E 1992 Prostate visualization studies in males homozygous and heterozygous for 5-a reductase deficiency. J Clin Endocrinol Metab 75:1022-6

52. Steers WD 2001 5alpha-reductase activity in the prostate. Urology 58:17-24; discussion 24.

53. Frick J, Aulitzky W 1991 Physiology of the prostate. Infection 19 Suppl 3:S115-8

54. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO 1998 A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride. Clinical Pharmacology & Therapeutics 64:636-647

55. Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC 1998 Influence of radical prostatectomy on serum hormone levels. J Urol 160:449-53

56. Toorians AW, Kelleher S, Gooren LJ, Jimenez M, Handelsman DJ 2003 Estimating the contribution of the prostate to blood dihydrotestosterone. J Clin Endocrinol Metab 88:5207-11

57. Zhu YS, Katz MD, Imperato-McGinley J 1998 Natural potent androgens: lessons from human genetic models. Baillieres Clin Endocrinol Metab 12:83-113

58. Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM, Graham-Lorence S, Sun T, Fisher CR, Qin K, Mendelson CR 1997 Aromatase expression in health and disease. Recent Prog Horm Res 52:185-213; discussion 213-4

59. Simpson ER 2003 Sources of estrogen and their importance. J Steroid Biochem Mol Biol 86:225-30

60. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS 1994 Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056-61

61. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O 1993 Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proceedings of the National Academy of Sciences USA 90:11162-6

62. Couse JE, Mahato D, Eddy EM, Korach KS 2001 Molecular mechanism of estrogen action in the male: insights from the estrogen receptor null mice. Reprod Fertil Dev 13:211-9

63. Carani C, Zini D, Baldini A, Casa LD, Ghizzani A, Marrama P 1990 Effects of androgen treatment in impotent men with normal and low levels of free testosterone. Archives of Sexual Behaviour 19:223-34

64. Bilezikian JP, Morishima A, Bell J, Grumbach MM 1998 Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339:599-603

65. Seeman E 1998 Growth in bone mass and size--are racial and gender differences in bone mineral density more apparent than real? Journal of Clinical Endocrinology & Metabolism 83:1414-9

66. Vanderschueren D, Van Herck E, Suiker AM, Visser WJ, Schot LP, Chung K, Lucas RS, Einhorn TA, Bouillon R 1993 Bone and mineral metabolism in the androgen-resistant (testicular feminized) male rat. J Bone Miner Res 8:801-9

67. Need AG, Nordin BEC, Chatterton BE 1993 Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic steroid nandrolone decanoate. Osteoporos Int Suppl 1:S218-22

68. Nebert DW, Russell DW 2002 Clinical importance of the cytochromes P450. Lancet 360:1155-62

69. Johnsen SG, Bennet EP, Jensen VG 1974 Therapeutic effectiveness of oral testosterone. Lancet ii:1473-1475

70. Frey H, Aakvag A, Saanum D, Falch J 1979 Bioavailability of testosterone in males. European Journal of Clinical Pharmacology 16:345-349

71. Parkes AS 1938 Effective absorption of hormones. Br Med J:371-373

72. Lisser H, Escamilla RF, Curtis LE 1942 Testosterone therapy of male eunuchoids. III Sublingual administration of testosterone compounds. Journal of Clinical Endocrinology 2:351-60

73. Korbonits M, Slawik M, Cullen D, Ross RJ, Stalla G, Schneider H, Reincke M, Bouloux PM, Grossman AB 2004 A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab 89:2039-43

74. Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, Veldhuis J, Dudley RE, Berman N, Davidson T, Barstow TJ, Sinow R, Alexander G, Swerdloff RS 1996 Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study. Journal of Clinical Endocrinology & Metabolism 81:3654-62

75. Shackleford DM, Faassen WA, Houwing N, Lass H, Edwards GA, Porter CJ, Charman WN 2003 Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther 306:925-33

76. Foss GL 1939 Clinical administration of androgens. Lancet i:502-504

77. O'Shaughnessy PJ, Baker P, Sohnius U, Haavisto AM, Charlton HM, Huhtaniemi I 1998 Fetal development of Leydig cell activity in the mouse is independent of pituitary gonadotroph function. Endocrinology 139:1141-6

78. Gromoll J, Eiholzer U, Nieschlag E, Simoni M 2000 Male hypogonadism caused by homozygous deletion of exon 10 of the luteinizing hormone (LH) receptor: differential action of human chorionic gonadotropin and LH. J Clin Endocrinol Metab 85:2281-6

79. Chin WW, Boime I (eds) 1990 Glycoprotein Hormones: Structure, Synthesis and Biologic Function. Serono Symposia, USA, Norwell

80. Muyan M, Furuhashi M, Sugahara T, Boime I 1996 The carboxy-terminal region of the beta-subunits of luteinizing hormone and chorionic gonadotropin differentially influence secretion and assembly of the heterodimers. Mol Endocrinol 10:1678-87

81. Dufau ML, Catt KJ 1978 Gonadotropin receptors and regulation of steroidogenesis in the testis and ovary. Vitam Horm 36:461-592

82. Cooke BA 1990 Is cyclic AMP an obligatory second messenger for luteinizing hormone? Mol Cell Endocrinol 69:C11-C15

83. Veldhuis JD, Carlson ML, Johnson ML 1988 The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. Proceedings of the National Academy of Science 84:7686-7690

84. Skinner MK 1991 Cell-cell interactions in the testis. Endocr Rev 12:45-77

85. Maddocks S, Setchell BP 1989 Effect of a single injection of human chorionic gonadotrophin on testosterone levels in testicular interstitial fluid, and in testicular and peripheral venous blood in adult rats. J Endocrinol 121:311-6

86. Hayes FJ, Seminara SB, Decruz S, Boepple PA, Crowley WF, Jr. 2000 Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab 85:3027-35

87. Hayes FJ, DeCruz S, Seminara SB, Boepple PA, Crowley WF, Jr. 2001 Differential regulation of gonadotropin secretion by testosterone in the human male: absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion. J Clin Endocrinol Metab 86:53-8

88. Quigley CA, DeBellis A, Marschke KB, El-Awady MK, Wilson EM, French FF 1995 Androgen receptor defects: historical, clinical and molecular perspectives. Endocr Rev 16:271-321

89. Heinlein CA, Chang C 2002 Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175-200

90. Liu PY, Death AK, Handelsman DJ 2003 Androgens and cardiovascular disease. Endocr Rev 24:313-40

91. Liu PY, Handelsman DJ 2004 Androgen therapy in non-gonadal disease. In: Nieschlag E, Behre HM (eds) Testosterone: Action, Deficiency and Substitution, 3rd ed. Springer-Verlag, Berlin, pp 445-95

92. Sorensen K 1987 Klinefelters syndrome in childhood, adolescence and youth: a genetic, clinical, developmental, psychiatric and psychological study. Parthenon Publishing, Chippenham

93. Nieschlag E, Nieschlag S, Behre HM 1993 Lifespan and testosterone. Nature 366:215

94. Bojesen A, Juul S, Gravholt CH 2003 Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab 88:622-6

95. Nieschlag E, Behre HM 1998 Pharmacology and clinical uses of testosterone. In: Nieschlag E, Behre HM (eds) Testosterone: Action Deficiency Substitution, 2nd ed. Springer-Verlag, Berlin, pp 293-328

96. Schaison G, Young J, Pholsena M, Nahoul K, Couzinet B 1993 Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 77:1545-9

97. Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF, Jr. 2002 Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 87:4128-36

98. Wang C, Tso SC, Todd D 1989 Hypogonadotropic hypogonadism in severe beta-thalassemia: effect of chelation and pulsatile gonadotropin-releasing hormone therapy. J Clin Endocrinol Metab 68:511-516

99. Liu PY, Gebski VJ, Turner L, Conway AJ, Wishart SM, Handelsman DJ 2002 Predicting pregnancy and spermatogenesis by survival analysis during gonadotropin treatment of gonadotropin deficient infertile men. Hum Reprod 17:625-33

100. Burger HG, de Kretser DM, Hudson B, Wilson JD 1981 Effects of preceeding androgen therapy on testicular response to human pituitary gonadotropin in hypogonadotropic hypogonadism. Fertil Steril 35:64-68

101. Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ, Catania JA 1983 Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab 57:71-77

102. Booth JD, Merriam GR, Clark RV, Loriaux DL, Sherins RJ 1987 Evidence for Leydig cell dysfunction in infertile men with a selective increase in plasma follicle-stimulating hormone. J Clin Endocrinol Metab 64:1194-1198

103. Howell SJ, Radford JA, Adams JE, Shalet SM 2000 The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition. Clin Endocrinol (Oxf) 52:609-16

104. Howell SJ, Radford JA, Smets EM, Shalet SM 2000 Fatigue, sexual function and mood following treatment for haematological malignancy: the impact of mild Leydig cell dysfunction. Br J Cancer 82:789-93

105. Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R, Shalet SM 2001 Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf) 55:315-24

106. Vermeulen A 1990 Androgens and male senescence. In: Nieschlag E, Behre HM (eds) Testosterone:Action Deficiency Substitution. Springer-Verlag, Berlin, pp 261-276

107. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ, Strom BL 1999 Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. Journal of Clinical Endocrinology & Metabolism 84:2647-53

108. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG, Jr., Strom BL 1999 Effect of testosterone treatment on bone mineral density in men over 65 years of age. Journal of Clinical Endocrinology & Metabolism 84:1966-72

109. Gruenewald DA, Matsumoto AM 2003 Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 51:101-15

110. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ 2001 A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 86:4078-88.

111. Liu PY, Wishart SM, Handelsman DJ 2002 A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 87:3125-35

112. Liverman CT, Blazer DG (eds) 2004 Testosterone and Aging: Clinical Research Directions. Institute of Medicine: The National Academies Press, Washington, DC

113. Ishak KG, Zimmerman HJ 1987 Hepatotoxic effects of the anabolic-androgenic steroids. Semin Liver Dis 7:230-236

114. Gelfand JA, Sherins RJ, Alling DW, Frank MM 1976 Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N Engl J Med 295:1444-1448

115. Agostini A, Cicardi M 1992 Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine- Baltimore 71:206-215

116. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R 1996 The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335:1-7

117. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, Bhasin S 2003 Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 88:1478-85

118. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, Bhasin S 2002 The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 87:136-43

119. Grunfeld C, Feingold KR 1992 Metabolic disturbances and wasting in the Acquired Immunodeficiency Syndrome. N Engl J Med 327:329-37

120. Kotler DP, Tierney AR, Wang J, Pierson RN 1989 Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 50:444-7

121. Bhasin S, Storer TW, Asbel-Sethi N, Kilbourne A, Hays R, Sinha-Hikim I, Shen R, Arver S, Beall G 1998 Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency- virus-infected men with low testosterone levels. J Clin Endocrinol Metab 83:3155-62

122. Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, Burrows B, Walsh M, Hayden D, Parlman K, Anderson E, Basgoz N, Klibanski A 1998 Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 129:18-26.

123. Grinspoon S, Corcoran C, Parlman K, Costello M, Rosenthal D, Anderson E, Stanley T, Schoenfeld D, Burrows B, Hayden D, Basgoz N, Klibanski A 2000 Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 133:348-55.

124. Sattler FR, Jaque SV, Schroeder ET, Olson C, Dube MP, Martinez C, Briggs W, Horton R, Azen S 1999 Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. Journal of Clinical Endocrinology & Metabolism 84:1268-76

125. Davis SR, Burger HG 2003 The role of androgen therapy. Best Pract Res Clin Endocrinol Metab 17:165-75

126. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, Goldstein I, Guay A, Leiblum S, Lobo R, Notelovitz M, Rosen R, Sarrel P, Sherwin B, Simon J, Simpson E, Shifren J, Spark R, Traish A 2002 Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 77:660-5

127. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B 1999 Dehydroepiandrosterone replacement in women with adrenal insufficiency N Engl J Med 341:1013-20

128. Greenblatt RB, Barfield WE, Garner JF, Calk GL, Harrod JP 1950 Evaluation of an estrogen, androgen, estrogen-androgen combination, and a placebo in the treatment of the menopause. J Clin Endocrinol Metab 10:1547-58

129. Sherwin BB, Gelfand MM 1987 The role of androgens in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 49:397-409

130. Urman B, Pride SM, Yuen BH 1991 Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol 77:1124-31

131. Baker J 1999 A report on alterations to the speaking and singing voices of four women following hormonal therapy with virilizing agents. J Voice 13:496-507

132. Davis SR, McCloud P, Strauss BJG, Burger H 1995 Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 21:227-36

133. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, Caramelli KE, Mazer NA 2000 Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343:682-8

134. Guzick DS, Hoeger K 2000 Sex, hormones, and hysterectomies. N Engl J Med 343:730-1

135. Hoberman JM, Yesalis CE 1995 The history of synthetic testosterone. Sci Am 272:76-81

136. Franke WW, Berendonk B 1997 Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem 43:1262-79

137. Haupt HA, Rovere GD 1984 Anabolic steroids: a review of the literature. Am J Sports Med 12:469-484

138. Wilson JD 1988 Androgen abuse by athletes. Endocr Rev 9:181-199

139. Elashoff JD, Jacknow AD, Shain SG, Braunstein GD 1991 Effects of anabolic-androgenic steroids on muscular strength. Ann Intern Med 115:387-393

140. Herbst KL, Bhasin S 2004 Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care 7:271-7

141. Buckley WE, Yesalis CE, Freidl KE, Anderson WA, Streit AL, Wright JE 1988 Estimated prevalence of anabolic steroid use among male high school students. Journal of the American Medical Association 260:3441-3445

142. Nilsson S 1995 Androgenic anabolic steroid use among male adolescents in Falkenberg. Europen Journal of Clinical Pharmacology 48:9-11

143. Handelsman DJ, Gupta L 1997 Prevalence and risk factors for anabolic-androgenic steroid abuse in Australian secondary school students. Int J Androl 20:159-64

144. Lambert MI, Titlestad SD, Schwellnus MP 1998 Prevalence of androgenic-anabolic steroid use in adolescents in two regions of South Africa. S Afr Med J 88:876-80

145. Ferenchick GS 1996 Validity of self-report in identifying anabolic steroid use among weightlifters. J Gen Intern Med 11:554-6

146. Pope HG, Kouri EM, Powell KF, Campbell C, Katz DL 1996 Anabolic-androgenic steroid use among 133 prisoners. Compr Psychiatry 37:322-7

147. Isacsson G, Garle M, Ljung EB, Asgard U, Bergmen U 1998 Anabolic steroids and violent crime - an epidemiological study at a jail in Stockholm, Sweden. Compr Psychiatry 39:203-5

148. Yesalis CE, Barsukiewicz CK, Kopstein AN, Bahrke MS 1997 Trends in anabolic-androgenic steroid use among adolescents. Arch Pediatr Adolesc Med 151:1197-206

149. Death AK, McGrath KC, Kazlauskas R, Handelsman DJ 2004 Tetrahydrogestrinone is a potent androgen and progestin. J Clin Endocrinol Metab 89:2498-500

150. Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang YC, Hatton CK 2004 Tetrahydrogestrinone: discovery, synthesis, and detection. Rapid Communication in Mass Spectrometry 18:1245-9

151. Holma PK 1977 Effects of an anabolic steroid (metandienone) on spermatogenesis. Contraception 15:151-162

152. Knuth UA, Maniera H, Nieschlag E 1989 Anabolic steroids and semen parameters in bodybuilders. Fertil Steril 52:1041-1047

153. Turek PJ, Williams RH, Gilbaugh JH, Lipshultz LI 1995 The reversibility of anabolic steroid-induced azoospermia. J Urol 153:1628-30

154. Sorensen M, Ingerslev HJ 1995 Azoospermia in two bodybuilders taking anabolic steroids. Ugeskr Laeger 157:1044-5

155. Gazvani MR, Buckett W, Luckas MJ, Aird IA, Hipkin LJ, Lewis-Jones DI 1997 Conservative management of azoospermia following steroid abuse. Hum Reprod 12:1706-8

156. Reyes RJ, Zicchi S, Hamed H, Chaudary MA, Fentiman IS 1995 Surgical correction of gynaecomastia in bodybuilders. Br J Clin Pract 49:177-9

157. Friedl KE 1990 Reappraisal of health risks associated with use of high doses of oral and injectable androgenic steroids. NIDA Res Monogr 102:142-77

158. Sklarek HM, Mantovani RP, Erens E, Heisler D, Niederman MS, Fein AM 1984 AIDS in a bodybuilder using anabolic steroids [letter]. N Engl J Med 311:1701

159. McClain WJ, Bucci KK 1988 Anabolic steroid use as an AIDS risk factor [letter]. Clin Pharm 7:95

160. Scott MJ, Scott MJ, Jr. 1989 HIV infection associated with injections of anabolic steroids [letter]. JAMA 262:207-8

161. Nemechek PM 1991 Anabolic steroid users--another potential risk group for HIV infection [letter]. N Engl J Med 325:357

162. Henrion R, Mandelbrot L, Delfieu D 1992 HIV contamination after injections of anabolic steroids (letter). Presse Med 21:218

163. Rich JD, Dickinson BP, Merriman NA, Flanigan TP 1998 Hepatitis C virus infection related to anabolic-androgenic steroid injection in a recreational weight lifter [letter]. Am J Gastroenterol 93:1598

164. Evans NA 1997 Local complications of self administered anabolic steroid injections. Br J Sports Med 31:349-50

165. Freeman BJ, Rooker GD 1995 Spontaneous rupture of the anterior cruciate ligament after anabolic steroids. Br J Sports Med 29:274-5

166. Pope HG, Katz DL 1988 Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry 145:487-490

167. Bahrke MS, Yesalis CE, Wright JE 1990 Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among male. A review. Sports Med 10:303-337

168. Rockhold RW 1993 Cardiovascular toxicity of anabolic steroids. Annu Rev Pharmacol Toxicol 33:497-520

169. Melchert RB, Welder AA 1995 Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc 27:1252-62

170. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ 1998 The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 41:1-15

171. Roberts JT, Essenhigh DM 1986 Adenocarcinoma of prostate in 40 year old body-builder. Lancet 2:742

172. Nakata S, Hasumi M, Sato J, Ogawa A, Yamanaka H 1997 Prostate cancer associated with long-term intake of patent medicine containing methyltestosterone: a case report. Hinyokika Kiyo - Acta Urologica Japonica 43:791-3

173. Yeater R, Reed C, Ullrich I, Morise A, Borsch M 1996 Resistance trained athletes using or not using anabolic steroids compared to runners: effects on cardiorespiratory variables, body composition, and plasma lipids. Br J Sports Med 30:11-4

174. Palatini P, Giada F, Garavelli G, Sinisi F, Mario L, Michieletto M, Baldo-Enzi G 1996 Cardiovascular effects of anabolic steroids in weight-trained subjects. J Clin Pharmacol New Drugs 36:1132-40

175. Dickerman RD, Schaller F, Zachariah NY, McConathy WJ 1997 Left ventricular size and function in elite bodybuilders using anabolic steroids. Clinical Journal of Sports Medicine 7:90-3

176. Jin B, Turner L, Walters WAW, Handelsman DJ 1996 Androgen or estrogen effects on the human prostate. J Clin Endocrinol Metab 81:4290-5

177. Sarna S, Sahi T, Koskenvuo M, Kaprio J 1993 Increased life expectancy of world class male athletes. Med Sci Sports Exerc 25:237-44

178. Kashkin KB, Kleber HD 1989 Hooked on hormones? An anabolic steroid addiction hypothesis. Journal of the American Medical Association 262:3166-3170

179. Fingerhood MI, Sullivan JT, Testa M, Jasinski DR 1997 Abuse liability of testosterone. J Psychopharmacol (Oxf) 11:59-63

180. Gill GV 1998 Anabolic steroid induced hypogonadism treated with human chorionic gonadotropin. Postgrad Med J 74:45-6

181. Boyadjiev NP, Georgieva KN, Massaldjieva RI, Gueorguiev SI 2000 Reversible hypogonadism and azoospermia as a result of anabolic-androgenic steroid use in a bodybuilder with personality disorder. A case report. J Sports Med Phys Fitness 40:271-4

182. Goldberg L, Elliot DL, Clarke GN, MacKinnon DP, Moe E, Zoref L, Green C, Wolf SL, Greffath E, Miller DJ, Lapin A 1996 Effects of a multidimensional anabolic steroid prevention intervention: the Adolescents Training and Learning to Avoid Steroids (ATLAS) program. Journal of the American Medical Association 276:1555-62

183. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E 1997 Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. Journal of Clinical Endocrinology & Metabolism 82:2386-90

184. Leifke E, Korner HC, Link TM, Behre HM, Peters PE, Nieschlag E 1998 Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. European Journal of Endocrinology 138:51-8

185. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R 1997 Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 82:407-13

186. Palacios A, Campfield LA, McClure RD, Steiner B, Swerdloff RS 1983 Effect of testosterone enanthate on hematopoesis in normal men. Fertil Steril 40:100-104

187. Jockenhövel F, Vogel E, Reinhardt W, Reinwein D 1997 Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 2:293-8

188. Davidson JM, Camargo CA, Smith ER 1979 Effects of androgens on sexual behaviour in hypogonadal men. J Clin Endocrinol Metab 48:955-958

189. Gooren LJ 1987 Androgen levels and sex functions in testosterone-treated hypogonadal men. Archives of Sexual Behaviour 16:463-73

190. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E 2003 Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab 88:2049-54

191. Avery MA, Tanabe M, Crowe DF, Detre G, Peters RH, Chong WKM 1990 Synthesis and testing of 17ab-hydroxy-7a methyl-D-homoestra-4,16-dien-3-one: a highly potent orally active androgen. Steroids 55:59-64

192. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD 1998 Discovery of nonsteroidal androgens. Biochemical & Biophysical Research Communications 244:1-4

193. Marhefka CA, Gao W, Chung K, Kim J, He Y, Yin D, Bohl C, Dalton JT, Miller DD 2004 Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J Med Chem 47:993-8

194. Lubahn D, Joseph DR, Sullivan PM, Williard HF, French FS, Wilson EM 1988 Cloning of the human androgen receptor complementary DNA and localisation to the X-chromosome. Science 240:327-330

195. Wilson JD 1980 The use and misuse of androgens. Metabolism 29:1278-1295

196. Negro-Vilar A 1999 Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 84:3459-62

197. Handelsman DJ, Conway AJ, Boylan LM 1990 Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 71:216-222

198. Deansley R, Parkes AS 1938 Further experiments on the administration of hormones by the subcutaneous implantation of tablets. Lancet ii:606-608

199. Handelsman DJ, Mackey MA, Howe C, Turner L, Conway AJ 1997 Analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol (Oxf) 47:311-6

200. Kelleher S, Turner L, Howe C, Conway AJ, Handelsman DJ 1999 Extrusion of testosterone pellets: a randomized controlled clinical study. Clinical Endocrinology. 51:469-471

201. Kelleher S, Conway AJ, Handelsman DJ 2002 A randomised controlled clinical trial of antibiotic impregnation of testosterone pellet implants to reduce extrusion rate. European Journal of Endocrinology. 146:513-8

202. Kelleher S, Conway AJ, Handelsman DJ 2001 Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clinical Endocrinology. 55:531-6

203. Handelsman DJ 1998 Clinical pharmacology of testosterone pellet implants. In: Nieschlag E, Behre HM (eds) Testosterone: Action Deficiency Substitution, 2nd ed. Springer, Berlin, pp 349-364

204. Bals-Pratsch M, Knuth UA, Yoon YD, Nieschlag E 1986 Transdermal testosterone substitution therapy for male hypogonadism. Lancet. 2:943-6

205. Findlay JC, Place VA, Snyder PJ 1987 Transdermal delivery of testosterone. Journal of Clinical Endocrinology & Metabolism 64:266-8

206. Bals-Pratsch M, Langer K, Place VA, Nieschlag E 1988 Substitution therapy of hypogonadal men with transdermal testosterone over one year. Acta Endocrinol (Copenh) 118:7-13

207. Jordan WP, Jr. 1997 Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am J Contact Dermat 8:108-13

208. Jordan WP, Jr., Atkinson LE, Lai C 1998 Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin Ther 20:80-7

209. Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, Odell WD 1992 Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 74:623-628

210. Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA 1997 Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf) 47:727-37

211. Bennett NJ 1998 A burn-like lesion caused by a testosterone transdermal system. Burns 24:478-80

212. Wilson DE, Kaidbey K, Boike SC, Jorkasky DK 1998 Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin Ther 20:299-306.

213. Guerin JF, Rollet J 1988 Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl 11:187-199

214. Chemana D, Morville R, Fiet J, Villette JM, Tabuteau F, Brerault JL, Passa P 1982 Percutaneous absorption of 5a-dihydrotestosterone in man. II Percutaneous administration of 5a-dihydrotestosterone in hypogonadal men with idiopathic haemochromatosis; clinical, metabolic and hormonal effectiveness. Int J Androl 5:595-606

215. Fiet J, Morville R, Chemana D, Villette JM, Gourmel B, Brerault JL, Dreux C 1982 Percutaneous absorption of 5a-dihydrotestosterone in man. I Plasma androgen and gonadotrophin levels in normal adult men after percutaneous administration of 5a-dihydrotestosterone. Int J Androl 5:586-594

216. Wang C, Iranmanesh A, Berman N, McDonald V, Steiner B, Ziel F, Faulkner SM, Dudley RE, Veldhuis JD, Swerdloff RS 1998 Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men--a clinical research center study. Journal of Clinical Endocrinology & Metabolism 83:2749-57

217. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N 2000 Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. Journal of Clinical Endocrinology & Metabolism 85:4500-10

218. Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N 2000 Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. Journal of Clinical Endocrinology & Metabolism 85:2839-53

219. Rolf C, Kemper S, Lemmnitz G, Eickenberg U, Nieschlag E 2002 Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men. Eur J Endocrinol 146:673-9

220. Delanoe D, Fougeyrollas B, Meyer L, Thonneau P 1984 Androgenisation of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception. Lancet i:276

221. Rolf C, Knie U, Lemmnitz G, Nieschlag E 2002 Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol (Oxf) 56:637-41

222. Burris AS, Ewing LL, Sherins RJ 1988 Initial trial of slow-release testosterone microspheres in hypogonadal men. Fertil Steril 50:493-497

223. Bhasin S, Swerdloff RS, Steiner B, Peterson MA, Meridores T, Galmirini M, Pandian MR, Goldberg R, Berman N 1992 A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J Clin Endocrinol Metab 74:75-83

224. Amory JK, Anawalt BD, Blaskovich PD, Gilchriest J, Nuwayser ES, Matsumoto AM 2002 Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men. J Androl 23:84-91

225. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F 1976 Enzyme induction by oral testosterone. Clin Pharmacol Ther 20:233-237

226. Stuenkel CA, Dudley RE, Yen SSC 1991 Sublingual administration of testosterone-hydroxyypropyl-b-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. J Clin Endocrinol Metab 72:1054-1059

227. Salehian B, Wang C, Alexander G, Davidson T, McDonald V, Berman N, Dudley RE, Ziel F, Swerdloff RS 1995 Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study. Journal of Clinical Endocrinology & Metabolism 80:3567-75

228. Dobs AS, Hoover DR, Chen MC, Allen R 1998 Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. Journal of Clinical Endocrinology & Metabolism. 83:33-9

229. Minto C, Howe C, Wishart S, Conway AJ, Handelsman DJ 1997 Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and volume. J Pharmacol Exp Ther 281:93-102

230. Snyder PJ, Lawrence DA 1980 Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 51:1335-1339

231. Cantrill JA, Dewis P, Large DM, Newman M, Anderson DC 1984 Which testosterone replacement therapy? Clin Endocrinol (Oxf) 24:97-107

232. Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ 1988 A randomised clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 11:247-264

233. Behre HM, Nieschlag E 1998 Comparative pharmacokinetics of testosterone esters. In: Nieschlag E, Behre HM (eds) Testosterone: Action Deficiency Substitution, 2nd ed. Springer, Berlin, pp 329-348

234. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ 1998 A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl 19:761-8

235. Nieschlag E, Buchter D, Von Eckardstein S, Abshagen K, Simoni M, Behre HM 1999 Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol (Oxf) 51:757-63.

236. von Eckardstein S, Nieschlag E 2002 Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 23:419-25

237. Weinbauer GF, Marshall GR, Nieschlag E 1986 New injectable testosterone ester maintains serum testosterone of castrated monkeys in the normal range for four months. Acta Endocrinol 113:128-132

238. Behre HM, Nieschlag E 1992 Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 75:1204-1210

239. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E 1995 Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 80:2394-2403

240. Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS 2003 Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 23:319-25

241. Gooren LJ 1994 A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 15:212-5.

242. Butler GE, Sellar RE, Walker RF, Hendry M, Kelnar CJH, Wu FCW 1992 Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. J Clin Endocrinol Metab 75:37-44

243. Luisi M, Franchi E 1980 Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. Journal of Endocrinological Investigations 3:305-308

244. Suvisaari J, Sundaram K, Noe G, Kumar N, Aguillaume C, Tsong YY, Lahteenmaki P, Bardin CW 1997 Pharmacokinetics and pharmacodynamics of 7a-methyl-19-nortestosterone after intramuscular administration in healthy men. Hum Reprod 12:967-73

245. Sundaram K, Kumar N, Bardin CW 1996 7a-methyl-19-nortestosterone (MENT): an ideal androgen for replacement therapy. In: Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C, Kelly C (eds) Pharmacology, Biology, and Clinical Applications of Androgens. Wiley-Liss, New York, pp 493-7

246. Sundaram K, Kumar N, Bardin CW 1993 7a-Methyl-nortestosterone (MENT): the optimal androgen for male contraception. Ann Med 25:199-205

247. Sundaram K, Kumar N, Monder C, Bardin CW 1995 Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens. Journal of Steroid Biochemistry & Molecular Biology 53:253-7

248. Anderson RA, Wallace AM, Sattar N, Kumar N, Sundaram K 2003 Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. J Clin Endocrinol Metab 88:2784-93

249. Place VA, Atkinson L, Prather DA, Trunnell N, Yates FE 1990 Transdermal testosterone replacement through genital skin. In: Nieschlag E, Behre HM (eds) Testosterone: Action, Deficiency, Substitution. Springer-Verlag, Berlin, pp 165-181

250. Behre HM, Oberpenning F, Nieschlag E 1990 Comparative pharmacokinetics of androgen preparations: application of computer analysis and simulation. In: Nieschlag E, Behre HM (eds) Testosterone: Action Deficiency Substitution. Springer-Verlag, Berlin, pp 115-135

251. Small M, Beastall GH, Semple CG, Cowan RA, Forbes CD 1984 Alterations of hormone levels in normal males given the anabolic steroid stanozolol. Clin Endocrinol (Oxf) 21:49-55

252. Christiansen K 1998 Behavioural correlates of testosterone. In: Nieschlag E, Behre HM (eds) Testosterone: Action Deficiency Substitution, 2nd ed. Springer, Berlin, pp 107-42

253. WHO Task Force on Methods for the Regulation of Male Fertility 1990 Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336:955-959

254. Anderson RA, Bancroft J, Wu FCW 1992 The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab 75:1503-1507

255. Buena F, Peterson MA, Swerdloff RS, Pandian MR, Steiner BS, Galmarini M, Lutchmansingh P, Bhasin S 1993 Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril 59:1118-23

256. Tricker R, Casaburi R, Storer TW, Clevenger B, Berman N, Shirazi A, Bhasin S 1996 The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men--a clinical research center study. J Clin Endocrinol Metab 81:3754-8

257. WHO Task Force on Methods for the Regulation of Male Fertility 1996 Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 65:821-9

258. Wu FCW, Farley TMM, Peregoudov A, Waites GMH, WHO Task Force on Methods for the Regulation of Male Fertility 1996 Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. Fertil Steril 65:626-36

259. Bjorkvist K, Nygren T, Bjorklund AC, Bjorkvist SE 1994 Testosterone intake and aggressiveness: real effect or anticipation? Aggressive Behavior 20:17-26

260. Archer J 1991 The influence of testosterone on human aggression. Br J Psychiatry 82:1-28

261. Su TP, Pagliaro M, Schmidt PJ, Pickar D, Wolkowitz O, Rubinow DR 1993 Neuropsychiatric effects of anabolic steroids in male normal volunteers. Journal of the American Medical Association 269:2760-4

262. Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V 1999 Psychosexual effects of three doses of testosterone cycling in normal men. Biol Psychiatry 45:254-60

263. Pope HG, Jr., Kouri EM, Hudson JI 2000 Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 57:133-40; discussion 155-6

264. Santamaria JD, Prior JC, Fleetham JA 1988 Reversible reproductive dysfunction in men with obstructive sleep apnea. Clin Endocrinol (Oxf) 28:461-470

265. Grunstein RR, Handelsman DJ, Lawrence SJ, Blackwell C, Caterson ID, Sullivan CE 1989 Hypothalamic dysfunction in sleep apnea: reversal by nasal continuous positive airways pressure. J Clin Endocrinol Metab 68:352-358

266. Sandblom RE, Matsumoto AM, Scoene RB, Lee KA, Giblin EC, Bremner WJ, Pierson DJ 1983 Obstructive sleep apnea induced by testosterone administration. N Engl J Med 308:508-510

267. Liu PY, Yee BJ, Wishart SM, Jimenez M, Jung DG, Grunstein RR, Handelsman DJ 2003 The short-term effects of high dose testosterone on sleep, breathing and function in older men. J Clin Endocrinol Metab 88:3605-13

268. Mackey MA, Conway AJ, Handelsman DJ 1995 Tolerability of intramuscular injections of testosterone ester in an oil vehicle. Hum Reprod 10:862-5

269. Nieschlag E, Wang C, Handelsman DJ, Swerdloff RS, Wu FCW, Einer-Jensen N, Waites GMH (eds) 1992 Guidelines For The Use Of Androgens In Men. Special Programme of Research, Development and Research Training in Human Reproduction of the World Health Organisation, Geneva

270. Kelleher S, Conway AJ, Handelsman DJ 2004 Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 90:(in press)

271. Mooradian AD, Morley JE, Korenman SG 1987 Biological actions of androgens. Endocr Rev 8:1-28

272. Wu JP, Gu FL 1987 The prostate 41-65 years post castration. Chin Med J (Engl) 100:271-2

273. Behre HM, Bohmeyer J, Nieschlag E 1994 Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 40:341-9

274. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA 1999 Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 84:3469-78

275. Jin B, Conway AJ, Handelsman DJ 2001 Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol (Oxf) 54:437-45.

276. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS 2000 Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18:847-53

277. Slater S, Oliver RT 2000 Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 17:431-9

278. Handelsman DJ 1998 The safety of androgens: prostate and cardiovascular disease. In: Wang C (ed) Male Reproductive Function. Kluwer Academic Publishers, Boston, pp 173-90

279. Kalin MF, Zumoff B 1990 Sex hormones and coronary disease: a review of the clinical studies. Steroids. 55:330-52

280. Wu FC, von Eckardstein A 2003 Androgens and coronary artery disease. Endocr Rev 24:183-217